Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARCAD Instillate is a biologic product candidate developed by ARC Pharmaceuticals for the prevention and treatment of post-surgical and fibrous adhesions. The active ingredient is fucoidan, a naturally occurring sulfated polysaccharide extracted from brown marine algae (seaweed). Formulated as a liquid instillate for direct application to tissues during surgery, the drug aims to reduce the incidence and severity of internal scarring. Fucoidan is thought to function by inhibiting selectin-mediated inflammatory cell recruitment and modulating the fibrinolytic system to prevent the formation of permanent fibrous bands between organs and tissues. The technology was licensed exclusively from the University of British Columbia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ARCAD Instillate.